The World Alzheimer's Disease Market (Incidence, Treatments, Key Companies, Pipeline and Trends)

   Single User - $1,500
   Corporate License - $4,995

Published Aug 1, 2008 | 125 Pages | Pub ID: KLI1614113

Alzheimer’s Disease is the most common cause of dementia, constituting 60% to 70% of all cases, and the risk with the disease doubles every 5 years after age 65. Incidence of the disease is increasing, and the resulting attention given to Alzheimer's Disease has encouraged development of new treatments. There is an opportunity for pharmaceutical companies to compete in this market, as Kalorama analyst Melissa Elder outlines in this study.

This report includes incidence of Alzheimer’s disease worldwide with information for specific geographical regions; world demographics; life expectancy by country, and other general issues affecting the market.

Information is presented as a worldwide overview, with special emphasis on the U.S., Japan, Germany, and other key markets.

A market summary includes market analysis by products on the market and in development, in addition to a a regional market analysis, including:

  • US
  • Europe
  • Japan
  • Rest of World
as well as a competitive analysis of leading providers. Additionally key company profiles are included, with profiles of the following companies competing in this therapeutic area:
  • Eisai Co., Ltd.
  • Forest Laboratories
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Merz Pharma GmbH
  • Novartis AG
  • Pfizer, Inc.
Markets are broken out by drug type:
  • Cholinesterase inhibitors
  • NMDA antagonists
as well as by product.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information.

For the purpose of this study, Kalorama Information conducted interviews with more than 50 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Additional interviews were completed with relevant company representatives including marketing directors, division managers, and product representatives.

All market data pertains to the world market at the manufacturers’ level. The base year for data was 2007. Historical data was provided for the years 2005 and 2006, with forecast data provided for 2008 through 2012. Compound annual growth rates (CAGRs) are provided for the 2005-2007 and 2008-2012 periods for each region and/or segment covered. Competitive analysis is provided for the year 2007.

In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times
We were unable to search inside this report.
No results matched your search criteria.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.